Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 8/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 8/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 7/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 6/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 6/20 | 1.00 |
| ▸ | GABRP | O00591 | 3/20 | 1.00 |
| ▸ | GABRD | O14764 | 3/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 3/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 3/20 | 1.00 |
| ▸ | GABRE | P78334 | 3/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 3/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 3/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delorazepam SCHEMBL32681132 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL29375434 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL29836158 | 0.90 | GABRA1 (0.81) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL7720989 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Phenazepam SCHEMBL416137 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| 7-Aminoclonazepam SCHEMBL11453747 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL9378946 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| N-Desalkyl-2-Oxoquazepam SCHEMBL30730010 | 0.87 | LMNA (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL11772087 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL16144652 | 0.87 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-20260062390-A1 | CONTINUOUS FLOW SYNTHESIS OF LORAZEPAM | PURDUE RESEARCH FOUNDATION | 2026-03-05 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| US-20240197751-A1 | Pharmaceutical composition and use thereof | BARNAS, ARIAN JANKUR CAN (AT) | 2024-06-20 | — | — | US | claimed |
| US-20240117436-A1 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | MAGI EUREGIO SCS (IT) | 2024-04-11 | — | — | US | claimed |
| WO-2024036115-A1 | CONTINUOUS FLOW SYNTHESIS OF LORAZEPAM | PURDUE RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | WO | claimed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| EP-1515702-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2004037230-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037259-A1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2003105808-A1 | ABUSE-PROTECTED ADMINISTRATION FORM | Grünenthal GmbH (DE) | 2003-12-24 | — | — | WO | claimed |
| WO-2003004015-A1 | OIL-IN-WATER EMULSIONS COMPRISING A BENZODIAZEPINE DRUG | WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (GB) | 2003-01-16 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-4595684-A | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | claimed |
| US-4511510-A | PHTHALIMIDOGLYCINE, HYDRAZINE | RAVIZZA S.P.A. (IT) | 1985-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062390-A1 | CONTINUOUS FLOW SYNTHESIS OF LORAZEPAM | GRIK4, GRIK5, POLM | GABRA1 201/4885GABRA5 58/4885GABRA3 192/4885 |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | PMP22, VHL, PAX8 | GABRA1 4061/4885GABRA5 4152/4885GABRA3 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.